Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23991225 | 0.78 | CA1 (0.42) | CA12CA1CA2CA9IDO1 | |
| SCHEMBL25745165 | 0.78 | CA12 (0.42) | CA12CA1CA2CA9IDO1 | |
| SCHEMBL30999078 | 0.76 | POLB (0.30) | POLB | |
| SCHEMBL30281102 | 0.76 | CA1 (0.46) | CA12CA1CA2CA9IDO1 | |
| SCHEMBL23989961 | 0.75 | KMT2A (0.49) | GAASMN1; SMN2RAB9AALDH1A1POLB | |
| SCHEMBL30999044 | 0.74 | POLB (0.32) | POLB | |
| SCHEMBL354093 | 0.74 | PKM (0.47) | PLK1GAASMN1; SMN2PKMRAB9A | |
| SCHEMBL22207679 | 0.72 | KMT2A (0.50) | GAASMN1; SMN2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL22207701 | 0.72 | KMT2A (0.33) | PLK1GAASMN1; SMN2PKMRAB9A | |
| SCHEMBL22207708 | 0.72 | CA12 (0.38) | CA12CA1CA2CA9IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252491-B2 | IL-17A inhibitors | ELI LILLY AND COMPANY (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3908585-B1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | LILLY CO ELI (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-113286795-B | Imidazo [1,2-b ] pyridazine IL-17A inhibitors | 伊莱利利公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20220073526-A1 | IL-17A INHIBITORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| US-20220073526-A1 | IL-17A INHIBITORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| EP-3908585-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-11-17 | — | — | EP | disclosed |
| CN-113286795-A | Imidazo [1,2-b ] pyridazine IL-17A inhibitors | 伊莱利利公司 | 2021-08-20 | — | — | CN | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252491-B2 | IL-17A inhibitors | IL17A, IL2, IL15 | CA12 4229/4885CA1 3486/4885CA2 2888/4885 |
| US-20220073526-A1 | IL-17A INHIBITORS | IL17A, IL2, IL15 | CA12 4229/4885CA1 3486/4885CA2 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.